NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Matcha, a vibrant green tea powder with ancient Japanese roots, has exploded in popularity worldwide. From traditional tea ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

pharmaphorum’s Managing Editor, Rebecca Aris, speaks with Gary Hendler of Eisai on Eisai’s current pipeline, what disease areas it will be focussing on and how its latest epilepsy drug ...